{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T01:48:45Z","timestamp":1781920125051,"version":"3.54.5"},"reference-count":88,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Traditional one size fits all pharmacotherapy often yields suboptimal clinical outcomes, preventable adverse drug reactions (ADRs), and significant drug waste, imposing substantial economic and ecological burdens on healthcare systems. This review evaluates the transformative potential of pharmacogenomics (PGx) testing, particularly cytochrome P450 (CYP) gene variants, as a foundation for an ecosystem-centric accountability framework for green pharmacy and links human metabolic variability to specific environmental outcomes. Personalized CYP profiling is shown to minimize the environmental release of unused drugs and potentially ecotoxic metabolites into aquatic ecosystems, in contrast to standard uniform drug use approaches. The limitations of ethnicity-based dosing models, which rely on population genetic variation, are examined in the context of increasing global genetic admixture. It is argued that individual genetic profiling, conceptualized as a PGx-Green Passport, provides a reliable safety standard that accounts for individual differences, thereby enhancing efficiency and well-being in a globalized society. By integrating clinical data, including real-world evidence on hospital utilization, with sustainability frameworks, this review demonstrates that PGx-guided therapy is not only a tool for clinical efficiency but also a fundamental requirement for systematically achieving environmentally sustainable healthcare.<\/jats:p>","DOI":"10.3390\/jpm16040183","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T14:33:33Z","timestamp":1774622013000},"page":"183","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Environmental and Global Impact of Pharmacogenomics: Advancing Green Pharmacy Toward Sustainable and Inclusive Precision Medicine"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-6554-0304","authenticated-orcid":false,"given":"P\u00e1lma","family":"Porrogi","sequence":"first","affiliation":[{"name":"Faculty of Health and Sport Sciences, Sz\u00e9chenyi Istv\u00e1n University, 9026 Gyor, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1002\/jcph.993","article-title":"Pharmacogenomics Implementation at the National Institutes of Health Clinical Center","volume":"57","author":"Sissung","year":"2017","journal-title":"J. Clin. Pharmacol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1080\/17512433.2022.2094767","article-title":"One Size Fits All? How to Optimize the Prescribing of Appropriate Polypharmacy in Chronic Diseases, Using a Behavioral Approach\u2014A United Kingdom Perspective","volume":"15","author":"Hughes","year":"2022","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1200\/JCO.2015.61.5997","article-title":"Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials","volume":"33","author":"Schwaederle","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2174\/1389200215666140130124910","article-title":"Incorporation of Pharmacogenomics into Routine Clinical Practice: The Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process","volume":"15","author":"Caudle","year":"2014","journal-title":"Curr. Drug Metab."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0140-6736(19)31276-0","article-title":"Pharmacogenomics","volume":"394","author":"Roden","year":"2019","journal-title":"Lancet"},{"key":"ref_6","first-page":"070","article-title":"Pharmacogenomics for Sustainable Drug Development: A Narrative Review of Precision Medicine, Green Chemistry, and Multi-Omics Innovation","volume":"16","author":"Lakshmi","year":"2026","journal-title":"J. Appl. Pharm. Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nature15817","article-title":"Pharmacogenomics in the Clinic","volume":"526","author":"Relling","year":"2015","journal-title":"Nature"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/clpt.2011.34","article-title":"Pharmacogenetics: From Bench to Byte\u2014An Update of Guidelines","volume":"89","author":"Swen","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/cpt.147","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors","volume":"98","author":"Hicks","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/clpt.2013.254","article-title":"Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update","volume":"95","author":"Crews","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1002\/cpt.2015","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing","volume":"109","author":"Lima","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/cpt.2903","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants","volume":"114","author":"Bousman","year":"2023","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1176\/appi.ajp.20230657","article-title":"Pharmacogenomic Clinical Support Tools for the Treatment of Depression","volume":"181","author":"Baum","year":"2024","journal-title":"Am. J. Psychiatry"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/s41397-022-00275-7","article-title":"Implementation of Pharmacogenomic Clinical Decision Support for Health Systems: A Cost-Utility Analysis","volume":"22","author":"Jiang","year":"2022","journal-title":"Pharmacogenomics J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/cpt.602","article-title":"Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium","volume":"101","author":"Cecchin","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1001\/jama.286.18.2270","article-title":"Potential Role of Pharmacogenomics in Reducing Adverse Drug Reactions: A Systematic Review","volume":"286","author":"Phillips","year":"2001","journal-title":"JAMA"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/gim.2016.87","article-title":"Standardizing Terms for Clinical Pharmacogenetic Test Results: Guidance from the Clinical Pharmacogenetics Implementation Consortium (CPIC)","volume":"19","author":"Caudle","year":"2017","journal-title":"Genet. Med."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Daughton, C.G., and Ruhoy, I.S. (2010). Reducing the Ecological Footprint of Pharmaceutical Usage: Linkages Between Healthcare Practices and the Environment. Green and Sustainable Pharmacy, Springer.","DOI":"10.1007\/978-3-642-05199-9_6"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Salei, E., Persson, C.L., and H\u00e5konsen, H. (2025). Green Pharmacy Practice\u2014A Multi Method Study of Environmental Sustainability Measures Implemented in Swedish Pharmacies. J. Pharm. Policy Pract., 18.","DOI":"10.1080\/20523211.2025.2512983"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1021\/cr020441w","article-title":"Human Pharmaceuticals in the Aquatic Environment: A Challenge to Green Chemistry","volume":"107","author":"Khetan","year":"2007","journal-title":"Chem. Rev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/clpt.2010.279","article-title":"CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network","volume":"89","author":"Relling","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Daughton, C.G. (2003). Cradle-to-Cradle Stewardship of Drugs for Minimizing Their Environmental Disposition While Promoting Human Health. II. Drug Disposal, Waste Reduction, and Future Directions. Environ. Health Perspect., 111.","DOI":"10.1289\/ehp.5948"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1016\/j.ajhg.2025.10.004","article-title":"The Clinical Pharmacogenetics Implementation Consortium\u2019s Consensus-Based Framework for Assigning Allele Function","volume":"112","author":"Tibben","year":"2025","journal-title":"Am. J. Hum. Genet."},{"key":"ref_24","unstructured":"(2026, February 06). Environmentally Sustainable Health Systems: A Strategic Document. Available online: https:\/\/www.who.int\/publications\/i\/item\/WHO-EURO-2017-2241-41996-57723."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nrg3352","article-title":"Cancer Pharmacogenomics: Strategies and Challenges","volume":"14","author":"Wheeler","year":"2013","journal-title":"Nat. Rev. Genet."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1056\/NEJMra020526","article-title":"Pharmacogenomics\u2014Drug Disposition, Drug Targets, and Side Effects","volume":"348","author":"Evans","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Alshemari, A., Breen, L., Quinn, G., and Sivarajah, U. (2020). Can We Create a Circular Pharmaceutical Supply Chain (CPSC) to Reduce Medicines Waste?. Pharmacy, 8.","DOI":"10.3390\/pharmacy8040221"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1146\/annurev-pharmtox-010814-124835","article-title":"Preemptive Clinical Pharmacogenetics Implementation: Current Programs in Five US Medical Centers","volume":"55","author":"Dunnenberger","year":"2014","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/clpt.2012.96","article-title":"Pharmacogenomics Knowledge for Personalized Medicine","volume":"92","author":"McDonagh","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/cpt.1489","article-title":"Development of the PGx-Passport: A Panel of Actionable Germline Genetic Variants for Pre-Emptive Pharmacogenetic Testing","volume":"106","author":"Jama","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Hamzic, S., Aebi, S., Joerger, M., Montemurro, M., Ansari, M., Amstutz, U., and Largiadr, C. (2020). Fluoropyrimidine Chemotherapy: Recommendations for DPYD Genotyping and Therapeutic Drug Monitoring of the Swiss Group of Pharmacogenomics and Personalised Therapy. Swiss Med. Wkly., 150.","DOI":"10.4414\/smw.2020.20375"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.2146\/ajhp160072","article-title":"Implementation of a multidisciplinary pharmacogenomics clinic in a community health system","volume":"73","author":"Dunnenberger","year":"2016","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.tips.2015.10.006","article-title":"Precision Medicine and Rare Genetic Variants","volume":"37","author":"Lauschke","year":"2016","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Zinken, J.F., Pasmooij, A.M.G., Ederveen, A.G.H., Hoekman, J., and Bloem, L.T. (2024). Environmental Risk Assessment in the EU Regulation of Medicines for Human Use: An Analysis of Stakeholder Perspectives on Its Current and Future Role. Drug Discov. Today, 29.","DOI":"10.1016\/j.drudis.2024.104213"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Lattanzio, S., Stefanizzi, P., D\u2019ambrosio, M., Cuscianna, E., Riformato, G., Migliore, G., Tafuri, S., and Bianchi, F.P. (2022). Waste Management and the Perspective of a Green Hospital\u2014A Systematic Narrative Review. Int. J. Environ. Res. Public Health, 19.","DOI":"10.3390\/ijerph192315812"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nature02626","article-title":"Moving towards Individualized Medicine with Pharmacogenomics","volume":"429","author":"Evans","year":"2004","journal-title":"Nature"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1146\/annurev-pharmtox-061724-080935","article-title":"Pharmacogenetic Panel Testing: A Review of Current Practice and Potential for Clinical Implementation","volume":"65","author":"Mosch","year":"2025","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Jeyavani, J., Sibiya, A., Stalin, T., Vigneshkumar, G., Al-Ghanim, K.A., Riaz, M.N., Govindarajan, M., and Vaseeharan, B. (2023). Biochemical, Genotoxic and Histological Implications of Polypropylene Microplastics on Freshwater Fish Oreochromis Mossambicus: An Aquatic Eco-Toxicological Assessment. Toxics, 11.","DOI":"10.3390\/toxics11030282"},{"key":"ref_39","unstructured":"(2026, March 11). Occurrence, Ecotoxicological Effects and Risk Assessment of Antihypertensive Pharmaceutical Residues in the Aquatic Environment\u2014A Review. Available online: https:\/\/www.researchgate.net\/publication\/278676558_Occurrence_ecotoxicological_effects_and_risk_assessment_of_antihypertensive_pharmaceutical_residues_in_the_aquatic_environment_-_A_review."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Samuel, G., and Lucassen, A.M. (2022). The Environmental Impact of Data-Driven Precision Medicine Initiatives. Camb. Prism. Precis. Med., 1.","DOI":"10.1017\/pcm.2022.1"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMra032424","article-title":"Drug Metabolism and Variability among Patients in Drug Response","volume":"352","author":"Wilkinson","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/AAFO2475","article-title":"Deprescribing Medicines in Older People Living with Multimorbidity and Polypharmacy: The TAILOR Evidence Synthesis","volume":"26","author":"Reeve","year":"2022","journal-title":"Health Technol. Assess. Winch. Engl."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/03602530902843483","article-title":"Polymorphism of Human Cytochrome P450 Enzymes and Its Clinical Impact","volume":"41","author":"Zhou","year":"2009","journal-title":"Drug Metab. Rev."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0165-6147(00)01717-X","article-title":"Genetic Susceptibility to Adverse Drug Reactions","volume":"22","author":"Pirmohamed","year":"2001","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"647","DOI":"10.2174\/138920011796504563","article-title":"The Risk of Adverse Drug Reactions in Older Patients: Beyond Drug Metabolism","volume":"12","author":"Onder","year":"2011","journal-title":"Curr. Drug Metab."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0140-6736(22)01841-4","article-title":"A 12-Gene Pharmacogenetic Panel to Prevent Adverse Drug Reactions: An Open-Label, Multicentre, Controlled, Cluster-Randomised Crossover Implementation Study","volume":"401","author":"Swen","year":"2023","journal-title":"Lancet"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/clpt.2013.105","article-title":"Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update","volume":"94","author":"Scott","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jcin.2017.07.022","article-title":"Multi-Site Investigation of Outcomes with Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy after Percutaneous Coronary Intervention","volume":"11","author":"Cavallari","year":"2018","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Zhou, Y., Nevosadov\u00e1, L., Eliasson, E., and Lauschke, V.M. (2023). Global Distribution of Functionally Important CYP2C9 Alleles and Their Inferred Metabolic Consequences. Hum. Genom., 17.","DOI":"10.1186\/s40246-023-00461-z"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/cpt.1477","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy","volume":"106","author":"Desta","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3111\/13696998.2015.1110160","article-title":"The Effect of Pharmacogenetic Profiling with a Clinical Decision Support Tool on Healthcare Resource Utilization and Estimated Costs in the Elderly Exposed to Polypharmacy","volume":"19","author":"Brixner","year":"2016","journal-title":"J. Med. Econ."},{"key":"ref_52","first-page":"55","article-title":"Pharmacogenetics of Cardiovascular Drug Therapy","volume":"6","author":"Peters","year":"2009","journal-title":"Clin. Cases Miner. Bone Metab."},{"key":"ref_53","unstructured":"(2026, February 06). Challenges in Clinical Implementation of CYP2D6 Genotyping: Choice of Variants to Test Affects Phenotype Determination\u2014Genetics in Medicine. Available online: https:\/\/www.gimjournal.org\/article\/S1098-3600(21)01108-4\/fulltext."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Zhang, L., Tholkes, A.J., Jones, K.C., Yang, L.J., Sieger, G.K., Cullen, K.R., Gunlicks-Stoessel, M.L., Mroz, P., Farley, J.F., and Johnson, S.G. (2025). Real-World Characterization of Psychiatric Pharmacogenomic Test Ordering and Clinical Relevance in Adults and Children. Clin. Transl. Sci., 18.","DOI":"10.1111\/cts.70297"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Molla, G., and Bitew, M. (2024). Revolutionizing Personalized Medicine: Synergy with Multi-Omics Data Generation, Main Hurdles, and Future Perspectives. Biomedicines, 12.","DOI":"10.3390\/biomedicines12122750"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1586\/ecp.11.6","article-title":"Green Pharmacy and pharmEcovigilance: Prescribing and the Planet","volume":"4","author":"Daughton","year":"2011","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"El Rouby, N., Allen, J.D., Koep, T., McIntyre, P., Kelly, J., Ramesh, A., Desai-Naik, A., Chiang, J., Patel, S., and Brueckner, C. (2025). Multi-Gene Pharmacogenomic Testing in a Community-Based Setting Is Feasible and Reduces Total Healthcare Costs. Clin. Transl. Sci., 18.","DOI":"10.1111\/cts.70418"},{"key":"ref_58","unstructured":"(2026, February 06). Table of Pharmacogenomic Biomarkers in Drug Labeling, Available online: https:\/\/www.fda.gov\/drugs\/science-and-research-drugs\/table-pharmacogenomic-biomarkers-drug-labeling."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/BF03256453","article-title":"The AmpliChip CYP450 Genotyping Test: Integrating a New Clinical Tool","volume":"10","author":"Susce","year":"2006","journal-title":"Mol. Diagn. Ther."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Barbarino, J.M., Whirl-Carrillo, M., Altman, R.B., and Klein, T.E. (2018). PharmGKB: A Worldwide Resource for Pharmacogenomic Information. Wiley Interdiscip. Rev. Syst. Biol. Med., 10.","DOI":"10.1002\/wsbm.1417"},{"key":"ref_61","unstructured":"(2026, February 06). GeneSight Testing: Your DNA Holds the Key to Finding the Right Antidepressant. Available online: https:\/\/www.reviveholisticpsychiatry.com\/post\/genesight-testing-your-dna-holds-the-key-to-finding-the-right-antidepressant."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Klomp, S.D., Manson, M.L., Guchelaar, H.-J., and Swen, J.J. (2020). Phenoconversion of Cytochrome P450 Metabolism: A Systematic Review. J. Clin. Med., 9.","DOI":"10.3390\/jcm9092890"},{"key":"ref_63","first-page":"13328","article-title":"Illustrative and historic cases of phenoconversion","volume":"13","author":"Michaud","year":"2021","journal-title":"Am. J. Transl. Res."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Auwerx, C., Sadler, M.C., Reymond, A., and Kutalik, Z. (2022). From Pharmacogenetics to Pharmaco-Omics: Milestones and Future Directions. Hum. Genet. Genom. Adv., 3.","DOI":"10.1016\/j.xhgg.2022.100100"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"de Jong, L.M., Boussallami, S., S\u00e1nchez-L\u00f3pez, E., Giera, M., Tushuizen, M.E., Hoekstra, M., Hawinkels, L.J.A.C., Rissmann, R., Swen, J.J., and Manson, M.L. (2023). The Impact of CYP2C19 Genotype on Phenoconversion by Concomitant Medication. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1201906"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/wsbm.1302","article-title":"Parsing Interindividual Drug Variability: An Emerging Role for Systems Pharmacology","volume":"7","author":"Turner","year":"2015","journal-title":"Wiley Interdiscip. Rev. Syst. Biol. Med."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"(2026, February 06). Real-World Impact of a Pharmacogenomics-Enriched Comprehensive Medication Management Program. Available online: https:\/\/www.mdpi.com\/2075-4426\/12\/3\/421.","DOI":"10.3390\/jpm12030421"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"(2026, February 06). Pharmaceutical Waste Management: A Comprehensive Analysis of Romanian Practices and Perspectives. Available online: https:\/\/www.mdpi.com\/2071-1050\/16\/15\/6571.","DOI":"10.3390\/su16156571"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jaci.2013.10.040","article-title":"Pharmacogenetics: Implications of Race and Ethnicity on Defining Genetic Profiles for Personalized Medicine","volume":"133","author":"Ortega","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/538161a","article-title":"Genomics Is Failing on Diversity","volume":"538","author":"Popejoy","year":"2016","journal-title":"Nature"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/978-1-0716-4003-6_13","article-title":"Machine Learning in Early Prediction of Metabolism of Drugs","volume":"2834","author":"Lettieri","year":"2025","journal-title":"Methods Mol. Biol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/cpt.690","article-title":"Worldwide Distribution of Cytochrome P450 Alleles: A Meta-analysis of Population-scale Sequencing Projects","volume":"102","author":"Zhou","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2217\/pgs.12.1","article-title":"Pharmacogenetics of antidepressant drugs: Current clinical practice and future directions","volume":"13","author":"Narasimhan","year":"2012","journal-title":"Pharmacogenomics"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/sj.leu.2401723","article-title":"Genetic Polymorphism of Thiopurine Methyltransferase and Its Clinical Relevance for Childhood Acute Lymphoblastic Leukemia","volume":"14","author":"McLeod","year":"2000","journal-title":"Leukemia"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Esper\u00f3n, P., Mart\u00ednez, M.F., Redal, M.A., Lazarowski, A., L\u00f3pez-Cort\u00e9s, A., Varela, N.M., and Qui\u00f1ones, L.A. (2022). Editorial: Pharmacogenetics and Pharmacogenomics in Latin America: Ethnic Variability, New Insights in Advances and Perspectives: A RELIVAF-CYTED Initiative. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.833000"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Salyakina, D., Roy, S., Wang, W., Oliva, M., Akhouri, R., Sotto, I., Mulas, N., Solano, R., Fernandez, J., and Sanchez, S. (2019). Results and Challenges of Cytochrome P450 2D6 (CYP2D6) Testing in an Ethnically Diverse South Florida Population. Mol. Genet. Genom. Med., 7.","DOI":"10.1002\/mgg3.922"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Aslam, M., Badshah, M., Abbasi, R., Sultan, A., Khan, K., Ahmad, N., and von Engelhardt, J. (2017). Further Evidence for the Association of CYP2D6*4 Gene Polymorphism with Parkinson\u2019s Disease: A Case Control Study. Genes Environ., 39.","DOI":"10.1186\/s41021-017-0078-8"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Wei, H., and Zhao, Q. (2025). CYP2D6 Polymorphism Rs1065852 Significantly Increases the Risk of Type 2 Diabetes. Ann. Med., 57.","DOI":"10.1080\/07853890.2025.2470956"},{"key":"ref_79","first-page":"2627","article-title":"Prevalence of the CYP2D6*10 (C100T), *4 (G1846A), and *14 (G1758A) alleles among Iranians of different ethnicities","volume":"9","author":"Bagheri","year":"2015","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"van der Wouden, C.H., Marck, H., Guchelaar, H.-J., Swen, J.J., and van den Hout, W.B. (2022). Cost-Effectiveness of Pharmacogenomics-Guided Prescribing to Prevent Gene-Drug-Related Deaths: A Decision-Analytic Model. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.918493"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"4708","DOI":"10.1111\/bph.15651","article-title":"Metabolomics Reveals Biomarkers in Human Urine and Plasma to Predict Cytochrome P450 2D6 (CYP2D6) Activity","volume":"178","author":"Magliocco","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"ref_82","unstructured":"(2026, February 06). Fip Statement of Policy: Environmental Sustainability within Pharmacy. Available online: https:\/\/www.researchgate.net\/publication\/377599848_FIP_STATEMENT_OF_POLICY_Environmental_sustainability_within_pharmacy."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"297","DOI":"10.30574\/wjbphs.2024.17.2.0070","article-title":"Artificial Intelligence-Driven Drug Interaction Prediction","volume":"17","author":"Sonaji","year":"2024","journal-title":"World J. Biol. Pharm. Health Sci."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2146\/ajhp100113","article-title":"Development and Implementation of a Pharmacist-Managed Clinical Pharmacogenetics Service","volume":"68","author":"Crews","year":"2011","journal-title":"Am. J. Health-Syst. Pharm. AJHP Off. J. Am. Soc. Health-Syst. Pharm."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/cts.12884","article-title":"Precision Medicine, AI, and the Future of Personalized Health Care","volume":"14","author":"Johnson","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Samuel, G., and Lucassen, A.M. (2022). The Environmental Sustainability of Data-Driven Health Research: A Scoping Review. Digit. Health, 8.","DOI":"10.1177\/20552076221111297"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Griffiths, J., Fox, L., and Williamson, P.R. (2024). Quantifying the Carbon Footprint of Clinical Trials: Guidance Development and Case Studies. BMJ Open, 14.","DOI":"10.1136\/bmjopen-2023-075755"},{"key":"ref_88","unstructured":"(2026, February 06). The Fate of Medicines after Use and Their Role in Environmental Pollution\u2014Pharmacy English Site 2026. Available online: https:\/\/pharmacy.uokerbala.edu.iq\/wp\/en\/blog\/2026\/01\/28\/the-fate-of-medicines-after-use-and-their-role-in-environmental-pollution\/."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/16\/4\/183\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T14:45:56Z","timestamp":1774622756000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/16\/4\/183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":88,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["jpm16040183"],"URL":"https:\/\/doi.org\/10.3390\/jpm16040183","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,27]]}}}